Vaccine Technology VIII

An ECI Conference Series

June 14-19, 2020
Melia Siges Hotel
Sitges, Spain

20AA hotel-melia-sitges

Mark Your Calendar!          Request for Next Mailing

Call for Abstracts!      Submission deadline for Oral and Posters:  Feb. 1, 2020

Please forward this link to colleagues who may be interested in the conference topic.

About This Conference

Vaccine Technology is the leading conference focused on the discovery, development and manufacture of vaccines. It brings together internationally leading experts to discuss the technologies and discoveries that have advanced vaccines for global needs.

The meeting content is organized by scientists from academia and industry and differentiates itself from commercial conferences by providing very high quality, cutting-edge scientific content.  The conference welcomes presentations from both academia and industry and will have dedicated sessions on the following topics.

  • Technological and Clinical Advances in Vaccinology
  • Next generation platforms
  • Bioprocessing advances in vaccine development and manufacturing
  • Formulation and delivery
  • Vaccine Analytics
  • Capacity building and intervention for emerging and reemerging infectious diseases
  • One world, one health

This conference has representation from around the world and is an outstanding opportunity for the exchange of ideas among scientists.  Many national and international organizations as well as the vaccine industry support this conference.  We will regularly update our website to inform about confirmed speakers, workshops, abstract submission and registration information.

Session Descriptions

Technological and clinical advances in vaccinology

Our understanding of both the immune system and the molecular biology of pathogens enable new strategies for prevention and treatment. Advances in synthetic biology, antigen design, therapeutic vaccines, and specific immune modulation are examples that will play prominent roles for the vaccinology of the 21st century. Coupled with this are the clinical needs to consider the appropriate animal models and correlates of protection for specific disease targets to give early read outs for novel candidates. With a systems vaccinology approach, it may become possible to direct antibody and T-cell mediated responses and increase our understanding of the range of response. This session is dedicated to recent advances in vaccinology that promise to improve efficacy, safety and availability of “next generation” vaccines.

(Keywords: novel vaccine candidates, clinical studies, antigen design, expression systems, therapeutic vaccines)


Florian Krammer, Icahn School of Medicine at Mount Sinai
Julià Blanco, IRSI Caixa
Barry Buckland, BioLogicB

Lead Speaker: 

Christian Brander, Universitat de Vic, Spain                        

Christian Brander graduated from the University of Bern in 1994 with a PhD in Immunology, having studied exogenous antigen re-presentation on HLA class and T-cell-mediated hyper-reactivity to penicillin. He spent the next 13 years at Harvard University, where he focused on cellular immunity to viral infections and the impact of host genetics on this immune response. He was awarded a Catalan Institute for Research and Advanced Studies (ICREA) senior professorship in 2008 to continue his work on host genetics and cellular immunity to viral infections, including HIV, HCV and herpesviruses such as Kaposi’s sarcoma-associated herpesvirus and Epstein-Barr virus. He is a curator of the Los Alamos HIV Immunology database and the scientific director of the Catalan HIVACAT programme for the development of effective preventive and therapeutic HIV vaccines. He holds associate professor positions at the Autonomous University of Barcelona (UAB) and at Vic University (UVic). He was rated among the most highly cited researchers of 2014 by Thompson Reuters         Website

Next generation platforms

The need to accommodate the incredible diversity of vaccine targets in a reproducible, consistent, and cost-effective manner requires the development of platform technologies. The increasing use of automation, data rich experimentation and standardized design means that it is now possible to create platform technologies for the design of antigens, rapid expression technologies to further their testing, development and manufacture. The advantages of the platform approach should enable faster development times, predictable cost of goods and de-risked scale-up or scale-out opportunities. Specific examples and case studies will be sought for this session that typify the potential of next generation platforms.

(Keywords: nucleic acid, protein, viral vector, continuous manufacturing, integrated production, holistic design)


Amine Kamen, McGill University, Canada
Sonia Trepanier, Medicago, Canada

Lead Speaker:

Leor Weinberger, University of California, USA


Bioprocessing advances in vaccine development and manufacture

The development and manufacture of vaccines often requires significant understanding of the upstream production conditions and downstream purification requirements of the antigen, such that each new antigen and vaccine target presents a novel and unique challenge. Advancing bioprocessing often requires better understanding of the experimental space which can be achieved through the implementation of high throughput methodologies, machine learning, quality by design approaches and the creation of novel unit operations that can increase the quality and productivity of the process. This session is dedicated to the advances made in bioprocessing for vaccine development and manufacture.

(Keywords: Upstream processing, downstream processing, integrated manufacturing, process analytical technologies, machine learning, high throughput methodologies, QbD)


Udo Reichi, Max Plank Magdeburg, Germany
Paula Alves, IBET, Portugal
Leda Castilho, University of Rio de Janeiro, Brazil
Manon Cox, NextWaveBio, USA
Nathalie Christian, Merck, USA

Lead Speaker:

Kathrin Jansen, Pfizer, USA


Vaccine Analytics

It encompasses all in vitro and in vivo assays to evaluate the biological, chemical and physical properties of a vaccine. In-depth characterization of vaccines provides an understanding on the function, potency and toxicity issues, and improves vaccine efficacy and safety. In addition, bio-analytical characterization plays a critical role in establishing comparability of the product produced with process, scale and site changes.

(Keywords: analytics, product characterization, product quality, release testing)



Laura Palomeres, UNAM
Sylvie Ulrich, Sanofi Pasteur
Isabelle Knott, GSK

Lead Speaker:

Isabelle Bekeredjian-Ding, Paul-Ehrlich Institute, Germany                  

Isabelle Bekeredjian-Ding is the Head of the Microbiology Division at the Paul-Ehrlich-Institut. She is a Medical Microbiologist and Immunologist and Associate Professor at the University of Bonn, Germany. She received her Medical School training at the University of Heidelberg, Padova (Italy) and Mt. Sinai in New York and the clinical training in Munich and Heidelberg. After a PhD equivalent in T cell and a postdoc in dendritic cell biology her research interest focused on immune recognition of infectious pathogens and microbiological methods. Before joining PEI she was deputy director of the Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany. Her current offices include Chair of the Innovative Medicines Initiative (IMI2 JU) Scientific Committee, CHMP Vaccines Working Party Member at the EMA and Lead of the Blood Working Group Subgroup for Infectious Pathogens of the German Ministry of Health.     Website


Formulation and Delivery

This session highlights the different steps that need to be taken in order to bring a concept to the first clinical trial, from the definition of the vaccine form (formulation, route of administration) to the various steps that need to be taken before entering into humans. Each vaccine candidate is unique and will require specific approach, nonetheless a common path can be defined and followed to maximize the chances of reaching a fast go/no go decision. Those paths will be discussed, including from how to select the formulation and validate its choice, to discussing the new emerging delivery and adjuvant technologies that are being brought to the field of vaccines.

(Keywords: drug product, delivery systems, devices, adjuvants)


David Volkin, University of Kansas, USA
Qinjian Zhao, Xiamen University, China
Lakshmi Khandke, PATH, USA

Lead Speaker:

Sangeeta Joshi, University of Kansas, USA


Capacity building and intervention for emerging and reemerging infectious diseases

Infectious diseases remain one of the two leading causes of global mortality. It is estimated that hundreds of thousand pathogens remain to be discovered and recent outbreaks including SARS, Ebola and Zika reveal major gaps in emergency response plans.  Initiatives, such as the Coalition for Epidemic Preparedness Innovations (CEPI) have been created to build on the global consensus that new and sustainable partnership models are needed to develop vaccines, diagnostics, and therapeutics to contain outbreaks of emerging and reemerging infectious diseases. Such partnerships should fill need for coordinated and proactive R&D and increased funding, stronger advanced development and manufacturing capabilities, regulatory innovations and harmonization of regulatory requirements. This session will provide a forum to highlight case studies on the accelerated development of new vaccines against emerging pathogens, and share views on novel strategies in building capacities to improve preparedness against emerging and reemerging infectious diseases.

(Keywords: Rapid response, neglected diseases, capacity building, epidemics)


Martin Elsenhawer, WHO

Lead Speaker:

Nicholas Havelange, CMC and Project Manager Consultant at CEPI        

Nicolas, a chemical and biotechnology engineer has more than 20 years of experience in the chemistry and biotechnology industries, with a specific focus on biomanufacturing and vaccines. He held diverse positions (i.e. process development, manufacturing, business development) at SmithKline Beecham Biologicals (now GSK Vaccines), Henogen (now Novasep-Henogen), Artelis/ATMI (now Pall LifeSciences), European Vaccine Initiative and CuraVac. Nicolas holds a Master in Chemical Engineering from Ecole Polytechnique de l’Université Libre de Bruxelles (ULB) and a Master in Molecular Biology and Biotechnology also from ULB.            Website

One world, one health

The vast majority of emerging and re-emerging pathogens in humans is of animal origin. Most of this growing number of threats has its origin in wildlife, while humans are exposed either directly or through indirect domestic animal contacts. Effective and economical ways of protecting mankind from emerging diseases are best based on combatting zoonotic pathogens at the animal source. The “One Health” concept creates awareness of the major opportunities that exist to protect public health through policies aimed at controlling these pathogens at the level of their animal hosts, or more specifically, at the interface between humans, animals and their environments. Implementation of these policies places those who have regular contacts with domestic animals, like owners, handlers and veterinarians, in the front line together with those who regularly come into contact with wildlife and their environment. This session will highlight the importance of the integration between medical and veterinary disciplines within the One Health concept.

(Keywords: animal vaccines, zoonotic, human-animal interface, environment)


Claudio Prieto, Universidad Nacional Del Litoral, Argentina
Bryan Charleston, Pirbright Institute, England
Jean-Christophe Audonnet, Merial, France

Lead Speakers:

Jean-Claude Manuguerra, Institute Pasteur, France        Website

Marion Koopmans, Viroscience Erasmus Medical Center, Netherlands       Website

Link to the recent past ECI conference on these topics.

Keynote Speakers

Jean-Marie Okwo-Bele,   Independent Public Health Consultant                       

Former Director of the Vaccines and Immunization Department, World Health Organization (WHO), Geneva (2004-2017). Brief Biography




David Robinson, BMGF                          

David Robinson joined the Bill & Melinda Gates Foundation in 2017 as deputy director, CMC Vaccines Development and Surveillance.  He and his team work with internal and external partners to develop and execute CMC strategies ad harness advances in science and technology that enable vaccine development to save lives in developing countries.  Website

Conference Organization


Tarit Mukhopadhyay, Merck, USA
Charles Lutsch, Sanofi Pasteur, USA
Linda Lua, University of Queensland, Australia
Francesc Godia, Universitat Autònoma de Barcelona, Spain

Abstract Submission

The abstracts should be submitted as soon as possible and no later than the deadlines noted below.  The abstract should consist of 5 parts:  purpose, method, results, conclusion, and reference.  The abstract should introduce the proposed paper’s subject, summarize its contents, explain any unique aspects, and clearly indicate the specific relevance to the themes of the Conference.

The abstract must be at least half a page in length with a one page maximum.

Session Descriptions  You may pick one or two sessions that you feel your work fits best.

Submission deadline is February 1, 2020 for both oral poster presentation.

Please prepare your abstract according to this template: docx or doc.

All abstracts should be submitted electronically HERE.

Only a limited number of oral presentation slots are available and thus all submissions for oral sessions will be considered for both oral and poster presentation.

Major Sponsors

Click on the logo to visit the website.

Level of Sponsorship

Please click HERE to view the sponsorship levels for this conference.

Conference Venue

Melia Siges Hotel – Conveniently located in a quiet area of Sitges, the Melia Sitges Hotel is just 3 minutes’ walk from Balmins and Aiguadolç beaches. It offers a spa, a stylish garden with an outdoor 20AA Melia Sitgespool, and a restaurant with a terrace. The Meliá Sitges is 5 minutes’ walk from Aiguadolç Marina and 10 minutes’ walk from the lively and historic town center. It is a 20-minute walk to the train station, which connects you with central Barcelona in just 40 minutes. The air-conditioned rooms at the Meliá feature modern, minimalist decor. Each one has a pillow menu and a flat-screen TV with satellite channels. Available for a surcharge, the hotel’s YHI spa includes a gym, hydromassage pool, sauna and steam bath. Massage treatments are also available. The Bistrot Saffron restaurant serves modern Mediterranean food. There is also a stylish cocktail bar with seating in the garden.

Sitges is a coastal town in Spain’s Catalonia region, about 35 km southwest of Barcelona, backed by the mountainous Parc Natural del Garraf. It is known for its Mediterranean beaches and seafront20AA Sitges old town promenade lined with grand mansions. A seaside town, Sitges boasts some beautiful beaches right on its doorstep. There are some 13 individually named beaches along a 2.5km promenade.  It has been referred to as the Saint-Tropez of Spain and the Jewel of the Mediterranean. The compact old town and surrounding streets are filled with shops, restaurants, and many nightspots.

Sitges is about a 20-minute drive from Barcelona’s El Prat international airport. It is not necessary to hire a car when staying in Sitges as there are excellent transport links to and from Barcelona airport and into Barcelona city.  For those who wish to spend some time in Barcelona either prior to or after the conference, Barcelona is easily accessible both by train and bus. The region can also be accessed from Reus and Girona airports with low cost airlines flying from many European airports.

The Maricel Museum and Cau Ferrat Museum showcase Catalan and other Spanish art.  The Cau 20AA Maricel Museum SitgesFerrat building was once the home of Catalan artist Santiago Rusiñol, one of the leading figures of the Catalan Modernist movement. Upon his death, the artist bequeathed the house and its contents – including drawings, paintings, ceramics and more – to the town of Sitges on condition that it be opened to the public as a museum.

If the Old Town of Sitges is not particularly large, it is nonetheless worth exploring, in particular the old fishermen’s neighborhood and its white houses with blue borders, as well as the 15th-century Church of Sant Bartomeu and Santa Tecla and its Baroque interior.  Sitges Old Town has typically Spanish narrow streets leading down to a palm tree lined promenade that runs along an open bay with its many beaches.

A wide pedestrian boulevard stretching along the waterfront, the Passeig Maritim is one of the most scenic walks to be enjoyed in Sitges. The walkway is lined with cafés, restaurants and ice cream shops.  The proximity to the sea is reflected in the cuisine of Sitges’ well-regarded traditional restaurants, which can be found along the waterfront and in the Old Town. The gastronomy of Catalonia is rich and varied. Principally it is the typical Mediterranean diet of fish and seafood with fresh vegetables, olives and olive oil rice and pasta.  Restaurants such as La Nansa and El Trull come highly recommended for their fresh fish as well as their hearty seafood rice dishes.

The town has been built on an industry of fishing, commerce and wine, and has been much favored by artists, the bohemian crowd and more recently has developed a large gay community.

If most people associate Bacardí Rum with Cuba, what they ignore is that the story actually begins in Spain – and more precisely Sitges – where founder Facundo Bacardí Massó was born in 1814. Today the Casa Bacardí talks of the brand’s heritage and the process of making rum, as well as offering the guests to try some rather delicious cocktails in the bar at the back.

Sitges is a maritime town. It has a large tourist infrastructure and facilities. With three local marinas, it has more than any other town in Spain. In addition to tourism, there are fishing, shoe-making, and artistic businesses, though the former now consist of smaller workshops. The town was rebuilt in the last century, to accommodate increased tourism. Noted for its outstanding location, the Church of Sant Bartomeu i Santa Tecla, better known as “La Punta” at the end of the promenade in a bastion above steps and a coastal cliff, has become one of the most recognized icons in Sitges, much photographed and painted. Its structure is quite peculiar, because it has two bell towers, and possesses one of the watch towers that served the population to calculate the time. Its facade is quite simple but the frame where it is located is incomparable. The beautiful parish of San Bartolome and Santa Tecla is certainly the image that symbolizes Sitges. The church, built in the seventeenth century but with many subsequent amendments, is a charming Baroque style and the interior retains several Renaissance and Baroque altars and an organ of 1690.

The word Sitges means “silo” in English and it refers to the underground holes used to store wine. Before the tourist and LGBT boom of the 60s and 70s, Sitges was a wine producing fishing village big in shoemaking and with a thriving artistic and cultural scene.  The name was given by the Sitges family who took over the town in the 12th century. However, the town’s history dates back to thousands of years ago, from the Neanderthal period when it is believed that humans inhabited the caves at either end of the town. A Neanderthal jaw found in the Cova del Gegant in the 1950’s dates back to 53,200 years ago and is one of the oldest human remains in Catalunya.

When the Spanish Civil War started, Sitges, like the rest of Catalunya, entered a dark period when all the artistic appeal and openness of the city was stopped and went into hibernation until the second half of the 20th century when things started to improve.  By the 60s and 70s, especially after Franco’s death, 75% of the population had moved from shoe making to tourism and most of the now famous festivals and cultural events that make the town proud and known were launched.  After Franco’s death in 1975 and the arrival of democracy, Sitges experienced a renewed boom. And the world famous Sitges Carnival, banned during the dictatorship, was re-established.

Melia Siges Hotel-  Joan Salvat Papasseit, 38  Barcelona – Sitges  Tel(34)93 811 0811


Conference Fees and Registration

Coming soon!

General Information about ECI

Engineering Conferences International (ECI) is a global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

The format of the weeklong research conference provides morning and late afternoon or evening sessions in which major presentations are made. Available time is included during the afternoons for ad hoc meetings, informal discussions, and/or recreation. This format is designed to enhance rapport among participants and promote dialogue on the development of the meeting. We believe that the conferences have been instrumental in generating ideas and disseminating information to a greater extent than is possible through more conventional forums.

All participants are expected both to attend the entire conference and to contribute actively to the discussions. The recording/photographing of lectures and presentations is forbidden. As ECI conferences take place in an informal atmosphere, casual clothing is the usual attire.

Engineering Conferences International
32 Broadway, Suite 314, New York, NY 10004
T: 1-212-514-6760 F: 1-212-514-6030 E: